FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:855-860 September 19, 1996 Number 12 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Ornithine transcarbamylase is an X-linked mitochondrial enzyme that catalyzes the synthesis of citrulline from carbamoyl phosphate and ornithine. A deficiency of this enzyme leads to hyperammonemia and hyperglutaminemia. In boys the disease is often fatal when its onset occurs during the neonatal period, but it is milder when onset occurs later in childhood. Heterozygous girls may be normal or may have episodes of hyperammonemic encephalopathy and decline in cognitive function. We report here on the long-term outcome in girls with ornithine transcarbamylase deficiency enrolled in studies of treatments designed to activate new pathways of waste-nitrogen excretion.

Methods We studied 32 girls (age, 1 to 17 years) with ornithine transcarbamylase deficiency who had had at least one episode of encephalopathy. The patients were assigned to treatment that consisted of sodium benzoate, alone or in combination with sodium phenylacetate or sodium phenylbutyrate, or sodium phenylbutyrate alone. Collaborating physicians provided clinical, metabolic, and developmental data at specified intervals.

Results Patients treated according to these protocols had greater than 90 percent survival at five years and maintained appropriate weight for height. The frequency of hyperammonemic episodes decreased with increasing age and with sodium phenylacetate or sodium phenylbutyrate treatment. Although the mean IQ before treatment was in the low average range, 19 of the 23 girls in whom intelligence was tested longitudinally had stable test scores.

Conclusions Girls with symptomatic ornithine transcarbamylase deficiency who are treated with drugs that activate new pathways of waste-nitrogen excretion have fewer hyperammonemic episodes and a reduced risk of further cognitive decline.

Source Information

From the Departments of Pediatrics (N.E.M., S.W.B., D.B.C.) and Psychiatry (S.S.B.), Johns Hopkins University School of Medicine, Baltimore.

Address reprint requests to Dr. Maestri at the Department of Pediatrics, Johns Hopkins Hospital, Park 336, 600 N. Wolfe St., Baltimore, MD 21287-2539.

Full Text of this Article

This article has been cited by other articles:

• Ito, H., Yoshimura, N., Kurosawa, M., Ishii, S., Nukina, N., Okazawa, H. (2009). Knock-down of PQBP1 impairs anxiety-related cognition in mouse. Hum Mol Genet 18: 4239-4254 [Abstract] [Full Text]  
• Yam, G. H.-F., Gaplovska-Kysela, K., Zuber, C., Roth, J. (2007). Sodium 4-Phenylbutyrate Acts as a Chemical Chaperone on Misfolded Myocilin to Rescue Cells from Endoplasmic Reticulum Stress and Apoptosis. IOVS 48: 1683-1690 [Abstract] [Full Text]  
• Ozcan, U., Yilmaz, E., Ozcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Gorgun, C. Z., Hotamisligil, G. S. (2006). Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes.. Science 313: 1137-1140 [Abstract] [Full Text]  
• Kolker, S., Hoffmann, G. F., Okun, J. G., Rose, C., Jalan, R., Haberle, J., Schliess, F., Haussinger, D. (2006). Congenital glutamine deficiency with glutamine synthetase mutations.. NEJM 354: 1093-1094 [Full Text]  
• Jarecki, J., Chen, X., Bernardino, A., Coovert, D. D., Whitney, M., Burghes, A., Stack, J., Pollok, B. A. (2005). Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum Mol Genet 14: 2003-2018 [Abstract] [Full Text]  
• Gardian, G., Browne, S. E., Choi, D.-K., Klivenyi, P., Gregorio, J., Kubilus, J. K., Ryu, H., Langley, B., Ratan, R. R., Ferrante, R. J., Beal, M. F. (2005). Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease. J. Biol. Chem. 280: 556-563 [Abstract] [Full Text]  
• Qi, X., Hosoi, T., Okuma, Y., Kaneko, M., Nomura, Y. (2004). Sodium 4-Phenylbutyrate Protects against Cerebral Ischemic Injury. Mol. Pharmacol. 66: 899-908 [Abstract] [Full Text]  
• Bonapace, G., Waheed, A., Shah, G. N., Sly, W. S. (2004). Chemical chaperones protect from effects of apoptosis-inducing mutation in carbonic anhydrase IV identified in retinitis pigmentosa 17. Proc. Natl. Acad. Sci. USA 101: 12300-12305 [Abstract] [Full Text]  
• Rimbaux, S, Hommet, C, Perrier, D, Cottier, J P, Legras, A, Labarthe, F, Lemarcis, L, Autret, A, Maillot, F (2004). Adult onset ornithine transcarbamylase deficiency: an unusual cause of semantic disorders. J. Neurol. Neurosurg. Psychiatry 75: 1073-1075 [Abstract] [Full Text]  
• Dasgupta, S., Zhou, Y., Jana, M., Banik, N. L., Pahan, K. (2003). Sodium Phenylacetate Inhibits Adoptive Transfer of Experimental Allergic Encephalomyelitis in SJL/J Mice at Multiple Steps. J. Immunol. 170: 3874-3882 [Abstract] [Full Text]  
• Nicolaides, P, Liebsch, D, Dale, N, Leonard, J, Surtees, R (2002). Neurological outcome of patients with ornithine carbamoyltransferase deficiency. Arch. Dis. Child. 86: 54-56 [Abstract] [Full Text]  
• Kurz, E. U., Wilson, S. E., Leader, K. B., Sampey, B. P., Allan, W. P., Yalowich, J. C., Kroll, D. J. (2001). The Histone Deacetylase Inhibitor Sodium Butyrate Induces DNA Topoisomerase II{alpha} Expression and Confers Hypersensitivity to Etoposide in Human Leukemic Cell Lines. Molecular Cancer Therapeutics 1: 121-131 [Abstract] [Full Text]  
• Yu, X., Thompson, M. M., Shi, D., Tuchman, M. (2001). Quantification of Benzoic, Phenylacetic, and Phenylbutyric Acids from Filter-Paper Blood Spots by Gas Chromatography-Mass Spectrometry with Stable Isotope Dilution. Clin. Chem. 47: 351-354 [Full Text]  
• Wraith, J E (2001). Current topic: Ornithine carbamoyltransferase deficiency. Arch. Dis. Child. 84: 84-88 [Full Text]  
• Segain, J-P, de la Bletiere, D R., Bourreille, A, Leray, V, Gervois, N, Rosales, C, Ferrier, L, Bonnet, C, Blottiere, H M, Galmiche, J-P (2000). Butyrate inhibits inflammatory responses through NFkappa B inhibition: implications for Crohn's disease. Gut 47: 397-403 [Abstract] [Full Text]  
• Redonnet-Vernhet, I., Rouanet, F., Pedespan, J. M., Hocke, C., Parrot, F. (2000). A successful pregnancy in a heterozygote for OTC deficiency treated with sodium phenylbutyrate. Neurology 54: 1008-1008 [Full Text]  
• Witzig, T. E., Timm, M., Stenson, M., Svingen, P. A., Kaufmann, S. H. (2000). Induction of Apoptosis in Malignant B Cells by Phenylbutyrate or Phenylacetate in Combination with Chemotherapeutic Agents. Clin. Cancer Res. 6: 681-692 [Abstract] [Full Text]  
• Lee, B., Yu, H., Jahoor, F., O'Brien, W., Beaudet, A. L., Reeds, P. (2000). In vivo urea cycle flux distinguishes and correlates with phenotypic severity in disorders of the urea cycle. Proc. Natl. Acad. Sci. USA 97: 8021-8026 [Abstract] [Full Text]